Difference between revisions of "Cefaly"

From HCE Wiki - The Human Cognitive Enhancement Wiki
Jump to: navigation, search
(update)
(Main characteristics: update)
Line 71: Line 71:
 
== Main characteristics ==
 
== Main characteristics ==
 
<!-- This section should describe the technology in more detail. Here should be information about the used hardware and software, available features, chemical composition and so on, provided that they are available. Second half of this section should offer information on history of the technology. When it was created, unveiled, developed, announced to the public or when it was available to purchase. Anything related to the technology that can be pinpointed to a certain date should be in this section together with relevant commentary.-->
 
<!-- This section should describe the technology in more detail. Here should be information about the used hardware and software, available features, chemical composition and so on, provided that they are available. Second half of this section should offer information on history of the technology. When it was created, unveiled, developed, announced to the public or when it was available to purchase. Anything related to the technology that can be pinpointed to a certain date should be in this section together with relevant commentary.-->
The Cefaly device consists of the headband with the electrode built in.  
+
The Cefaly neurostimulator has two forms according to position of the electrode:<ref>Two types of electrodes: http://www.cefaly.com/en/cefaly-electrodes (retrieved Jan 28, 2016)</ref>
 +
1. Forehead electrode - device consists of the headband with the electrode built in.  
 +
2. Occipital electrode - inbuilt in the "Arnold kit"
  
The company also offers Cefaly to rent for 49 € per 2-month trial period. This is possible only on condition of paying the 295 €. If customer is dissatisfied, the company will pay him/her back 246 €.<ref>TRYING CEFALY on Cefaly official online-shop: http://www.cefaly.com/en/cefaly-shop (retrieved Jan 28, 2016)</ref>
+
In the UK and Ireland, The company also offers Cefaly to rent for 49 € per 2-month trial period. This is possible only on condition of paying the 295 €. If customer is dissatisfied, the company will pay him/her back 246 €.<ref>TRYING CEFALY on Cefaly official online-shop: http://www.cefaly.com/en/cefaly-shop (retrieved Jan 28, 2016)</ref>
  
  
 
=== Purpose ===
 
=== Purpose ===
 
<!-- This is a very short description of the technology's purpose. What will it be doing, for what goal was it created, how it modifies human cognition. Keep this as brief as possible. -->
 
<!-- This is a very short description of the technology's purpose. What will it be doing, for what goal was it created, how it modifies human cognition. Keep this as brief as possible. -->
 
+
The electrode sends electrical impulses through the skin to branches of the trigeminal nerve.
  
 
=== Company & People ===
 
=== Company & People ===

Revision as of 01:33, 28 January 2016

CEFALY
Cefaly.jpg
Category Head-mounted devices
Developer STX-Med
Announced 2014[1]
Released Consumers: 2015[2]
Price 295 USD [3]
Weight 45.4 g [4]
Dimensions mm
Controls smartphone
Standalone[5]
http://www.cefalytechnology.com/en/company
http://www.cefalytechnology.com/en/products

Cefaly is head-mounted wearable developed in purpose to treat and prevent migraine.


Main characteristics

The Cefaly neurostimulator has two forms according to position of the electrode:[6] 1. Forehead electrode - device consists of the headband with the electrode built in. 2. Occipital electrode - inbuilt in the "Arnold kit"

In the UK and Ireland, The company also offers Cefaly to rent for 49 € per 2-month trial period. This is possible only on condition of paying the 295 €. If customer is dissatisfied, the company will pay him/her back 246 €.[7]


Purpose

The electrode sends electrical impulses through the skin to branches of the trigeminal nerve.

Company & People

STX-Med company

Founders:

Pierre Rigaux

Pierre-Yves Muller

Important Dates

2004 - Foundation of STX-Med, which was later named Cefaly.[1]

Ethical Issues

Health Risks

Right on the official page of Cefaly side effects are stated.[2] Company claims, that side effects appear in 4,3% of patients, mentioning most common as intolerance to the feeling of Cefaly on the forehead (1.25%), sensation of fatigue during and after the session (0.65%), headache after one session (0.52%), or irritation of the skin on the forehead (0.22%).


Skin irritated probably because of electrode gel containing acrylate.[8]

Enhancement/Therapy/Treatment

Electrode sends electric current through skin and affects trigeminal nerve.[8]

Public & Media Impact and Presentation

Cefaly has its own official facebook page since 2009, and after this, several pages about Cefaly for specific countries were created.

Public Policy

Announcement about approving migraine treat

Memo clearance

Related Technologies, Project or Scientific Research

References

  1. FDA approves device to treat migraine headaches: http://articles.latimes.com/2014/mar/11/science/la-sci-sn-fda-approves-device-to-prevent-migraine-headaches-20140311
  2. Cefaly Technology release: http://www.biospace.com/News/cefaly-technology-release-10000-u-s-migraine/361631 (retrieved Jan 28, 2016)
  3. Cefaly Set on the Cefaly official online-shop: http://www.cefalymedical.com/shop/traitement-migraine/english_a/set-cefaly.html (retrieved Jan 28, 2016)
  4. Cefaly® Anti-migrain Device: http://www.amazon.co.uk/Cefaly-Cefaly%C2%AE-Anti-migraine-Device/dp/B009VPAS0M (retrieved Jan 28, 2016)
  5. Shows if the device is a standalone wearable computer or if it needs to be connected to a processing unit to function.
  6. Two types of electrodes: http://www.cefaly.com/en/cefaly-electrodes (retrieved Jan 28, 2016)
  7. TRYING CEFALY on Cefaly official online-shop: http://www.cefaly.com/en/cefaly-shop (retrieved Jan 28, 2016)
  8. 8.0 8.1 Magis D., Sava S., d’Elia T. S., Baschi R., Schoenen J., Safety and patients’ satisfaction of transcutaneous Supraorbital NeuroStimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177534/